Latest:
Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL
Tom van Meerten, MD, PhD, outlines select patient subgroups with BTK inhibitor–naive relapsed/refractory MCL who may benefit from treatment with brexu-cel.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Naseema Gangat, MBBS
Naseema Gangat, MBBS, is a professor of medicine and a consultant in hematology at Mayo Clinic in Rochester, Minnesota.
Latest:
Dr Gangat on Ruxolitinib as the Standard of Care in Myelofibrosis
Naseema Gangat, MBBS, discusses the JAK inhibitor ruxolitinib as the standard of care for the treatment of patients with myelofibrosis.
Nicholas Shawn Whipple, MD, MPH
Latest:
Expert Perspectives and Key Takeaways in pLGG Management
Experts discuss pediatric low-grade glioma (pLGG) as the most common childhood central nervous system (CNS) tumor, emphasizing a personalized, collaborative approach that integrates evolving molecular insights and patient factors to tailor treatments, improve quality of life, and offer hope through ongoing research and multidisciplinary care.
Roman Groisberg, MD
Latest:
Sarcoma, the “Forgotten Cancer”: Examining What’s Needed to Improve Care
Sarcomas, all together, have an incidence of less than 5/100,000 persons per year, according to the Surveillance, Epidemiology, and End Results Program. Compare that with breast cancer, which impacts 129.1/100,000 women per year, or lung cancer, which has an incidence of 53.1/100,000 persons per year
Ivy Riano, MD
Latest:
Adopting Broader Clinical Trial Eligibility in Lung Cancer With Brain Mets, Leptomeningeal Disease
Ivy Riano, MD, of Dartmouth Geisel School of Medicine, discusses the adoption of broader clinical trial eligibility in lung cancer, specifically for those with brain metastases or leptomeningeal disease.
R. Alejandro Sica, MD
Latest:
Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic Features
Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.
Karie Danielle Keera Runcie, MD
Karie Danielle Keera Runcie, MD, is the assistant professor of medicine at Columbia University Irving Medical Center and a medical oncologist at NewYork-Presbyterian/Columbia.
Latest:
Dr Runcie on the Mechanism of Action of XmAb30819 in ccRCC
Karie Runcie, MD, discusses the mechanism of action of XmAb30819 in clear cell RCC.
Rutgers Cancer Institute of New Jersey
Latest:
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Retains its Position as New Jersey’s Only National Cancer Institute-Designated Comprehensive Cancer Center
Rutgers Cancer Institute of New Jersey along with RWJBarnabas Health was redesignated by the National Cancer Institute.
Paul Hanona, MD
Paul Hanona, MD, is the chief Hematology Oncology Fellow at Beaumont Health
Latest:
Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD
Drs Park and Hanona discuss the ways that public health content creation offers practical advice about a variety of topics but may also spark debate.
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD, is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope
Latest:
Highlighting Key ALL Updates and Data From EHA 2025
Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss key data in acute lymphoblastic leukemia presented at the 2025 EHA Congress.
Everett Meyer, MD, PhD
Latest:
Unanswered Questions and the Future for Orca-T: What’s Next?
Panelists discuss how unanswered questions regarding long-term outcomes and potential late toxicities, along with the need for further evaluation in specific patient subgroups, highlight the importance of continued research to refine the use of Orca-T across diverse populations.